B
APLS

Braidwell’s Apellis Pharmaceuticals APLS Stock Holding History

Braidwell’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,121,034
Closed -$19.4M – 74
2025
Q2 		$19.4M Sell
1,121,034
-531,300
-32% -$9.83M 0.66% 38
2025
Q1 		$36.1M Sell
1,652,334
-446,532
-21% -$12.3M 1.27% 33
2024
Q4 		$67M Sell
2,098,866
-1,026,317
-33% -$30.9M 1.99% 17
2024
Q3 		$90.1M Buy
3,125,183
+2,513,383
+411% +$93.1M 2.55% 10
2024
Q2 		$23.5M Buy
+611,800
New +$27.7M 0.74% 44
2023
Q1 		– Sell
-389,596
Closed -$20.1M – 84
2022
Q4 		$20.1M Buy
+389,596
New +$20.7M 0.68% 52

Other funds holding APLS

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Braidwell's APLS Position: Q3 2025 in Review

Braidwell sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 1,121,034 shares — an estimated $19.4M sold.

Braidwell first reported a position in APLS in Q4 2022 and held it in 6 quarters. The position peaked at $90.1M in Q3 2024. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Braidwell reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Braidwell sold 1,121,034 Apellis Pharmaceuticals shares in Q3 2025, an estimated $19.4M.
  • Braidwell first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Braidwell's Apellis Pharmaceuticals position peaked at $90.1M in Q3 2024.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Braidwell's 13F filing for Q3 2025, filed 14 Nov 2025.